Document is current

Any future updates will be listed below

Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia

Crossref DOI link: https://doi.org/10.1007/s00277-017-3021-y

Published Online: 2017-06-17

Published Print: 2017-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark